Cross Linking News and Research

RSS

FDA grants priority review status to Avedro's riboflavin ophthalmic solution/KXL system

Avedro Inc, a Boston-based ophthalmic medical device and pharmaceutical company announces that it received notification from the U.S. Food and Drug Administration stating that their NDA for riboflavin ophthalmic solution/KXL system has been filed, and has been granted priority review status. The priority review status places the application action date at March 15th, 2014.

25 Nov 2013

Avedro initiates US clinical trials for Lasik with cross-linking and pulsed accelerated cross-linking

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces today that the first patients have been treated in two new US clinical trials: Lasik with Cross-linking and Pulsed Accelerated Cross-linking.

12 Nov 2013

Avedro gets CE Mark clearance for KXL II System

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces CE Mark clearance for its KXL II System. The KXL II System has the potential for non-surgical correction of myopia, as well as improving cataract surgery outcomes, with a procedure called PiXL (Photorefractive Intrastromal Cross-linking).

5 Nov 2013

Research findings open up possibility for developing potent anti-clotting drugs

Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing. By blocking this switch in lab mice, the researchers prevented small clots from growing -- a process that can pose a danger in humans -- while preserving their ability to staunch bleeding

29 Oct 2013

Modern strains of MRSA have become broadly resistant to antibiotics: Study

University of Notre Dame researchers Shahriar Mobashery and Mayland Chang and their collaborators in Spain have published research results this week that show how methicillin-resistant Staphylococcus aureus (MRSA) regulates the critical crosslinking of its cell wall in the face of beta-lactam antibiotics.

5 Oct 2013

New reagent kits for intracellular staining from Beckman Coulter Life Sciences

PerFix-Expose1 and PerFix-nc1, innovative new reagent kits for intracellular staining from Beckman Coulter Life Sciences, minimize sample manipulation for a streamlined workflow that delivers high quality results. Developed for use on Beckman Coulter’s Gallios1 and Navios2 series flow cytometers and compatible with all Beckman Coulter Life Sciences’ fluorochromes, the kits enable a clear focus on the cytoplasmic and nuclear compartments of the cell.

8 Aug 2013

MemoryShape Breast Implants receive FDA approval

The U.S. Food and Drug Administration today approved the MemoryShape Breast Implant to increase breast size (augmentation) for use in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age.

15 Jun 2013

Promising step toward safer, more comfortable implants

Researchers led by scientists at Case Western Reserve University have turned to an unlikely model to make medical devices safer and more comfortable-a squid's beak.

4 Apr 2013

Hatch Medical receives two US patents for percutaneous spinal stabilization system

Medical device incubator and technology brokerage firm, Hatch Medical, L.L.C. today announced the issuance of US Patent No. 8,357,197 and US Patent No. 8,357,198 related to their percutaneous spinal stabilization system.

20 Mar 2013

Avedro announces completion of $43M Series D financing

Avedro, Inc. announced today the completion of a $43 million Series D financing led by Abingworth along with a significant investment by Third Point.

5 Mar 2013

Allergan receives FDA approval for Natrelle 410 breast implant

The U.S. Food and Drug Administration today approved the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Gel Filled Breast Implant to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. Natrelle 410 implants are manufactured by Allergan, Inc.

20 Feb 2013

New materials mimic mussel adhesive proteins for three medical applications

When it comes to sticking power under wet conditions, marine mussels are hard to beat. They can adhere to virtually all inorganic and organic surfaces, sustaining their tenacious bonds in saltwater, including turbulent tidal environments.

18 Feb 2013

Part of Human Brain Project focuses on Neurorobotics

Extensive knowledge about the human brain and its functioning already exists but is highly fragmented. The goal of the Human Brain Project is to pull together this knowledge and to reconstruct the brain, piece by piece, in supercomputer-based models and simulations. The models offer the prospect of a new understanding of the human brain and its diseases and of completely new computing and robotic technologies.

29 Jan 2013

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

Researchers develop unique approach to calpain inhibition

Calpain, a calcium-regulated enzyme, is essential to a host of cellular processes, but can cause severe problems in its overactivated state. It has been implicated as a factor in muscular dystrophy, AIDS, Alzheimer's disease, multiple sclerosis, and cancer. As such, finding and exploiting calpain inhibitors is an important area of research.

28 Dec 2012

Novel organic metamaterial holds promise for drug delivery

A bit reminiscent of the Terminator T-1000, a new material created by Cornell researchers is so soft that it can flow like a liquid and then, strangely, return to its original shape.

7 Dec 2012

Sourdough and enzyme bioprocessing effectively modify flavor, texture of oat breads

The health-promoting properties of whole grain oat have made it a desirable ingredient for use in breads. However, the absence of gluten-forming proteins and high fibre content pose technological challenges with respect to product texture. Fundamental understanding about the role of oat components on the structure formation of dough and bread is needed to facilitate the development of new healthy variants of oat breads with consumer appealing properties.

5 Dec 2012

New type of drug for drug-resistant cancer

New drug may be an effective alternative for patients whose cancer is resistant to currently available drugs.

4 Oct 2012

HDL may protect against abdominal aortic aneurysm

High levels of high-density lipoprotein cholesterol inhibit the formation of abdominal aortic aneurysm, findings from experimental mouse models suggest.

2 Oct 2012

Researchers obtain first detailed and complete picture of PRC2 protein

The first detailed and complete picture of a protein complex that is tied to human birth defects as well as the progression of many forms of cancer has been obtained by an international team of researchers led by scientists with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab).

18 Sep 2012